about
RB loss in resistant EGFR mutant lung adenocarcinomas that transform to small-cell lung cancer.Phase I trial of Seneca Valley Virus (NTX-010) in children with relapsed/refractory solid tumors: a report of the Children's Oncology Group.Evaluation of azacitidine and entinostat as sensitization agents to cytotoxic chemotherapy in preclinical models of non-small cell lung cancerSeneca Valley Virus 3Cpro Substrate Optimization Yields Efficient Substrates for Use in Peptide-Prodrug TherapyRapamycin rescues ABT-737 efficacy in small cell lung cancerDesign, execution, and analysis of pooled in vitro CRISPR/Cas9 screens.DNA methylation in small cell lung cancer defines distinct disease subtypes and correlates with high expression of EZH2.Quantitation of Murine Stroma and Selective Purification of the Human Tumor Component of Patient-Derived Xenografts for Genomic AnalysisCD47-blocking immunotherapies stimulate macrophage-mediated destruction of small-cell lung cancer.P-selectin is a nanotherapeutic delivery target in the tumor microenvironment.Selective tropism of Seneca Valley virus for variant subtype small cell lung cancer.Unravelling the biology of SCLC: implications for therapy.Targeted Imaging of the Atypical Chemokine Receptor 3 (ACKR3/CXCR7) in Human Cancer Xenografts.Upregulation of MMP-2 by HMGA1 promotes transformation in undifferentiated, large-cell lung cancer.Next-Generation Sequencing of Pulmonary Large Cell Neuroendocrine Carcinoma Reveals Small Cell Carcinoma-like and Non-Small Cell Carcinoma-like Subsets.Anthrax toxin receptor 1 is the cellular receptor for Seneca Valley virus.Noninvasive Interrogation of DLL3 Expression in Metastatic Small Cell Lung Cancer.Chemosensitive Relapse in Small Cell Lung Cancer Proceeds through an EZH2-SLFN11 Axis.PARP Inhibitor Activity Correlates with SLFN11 Expression and Demonstrates Synergy with Temozolomide in Small Cell Lung Cancer.RET mutations in neuroendocrine tumors: including small-cell lung cancer.Keap1 loss promotes Kras-driven lung cancer and results in dependence on glutaminolysis.Correction: Seneca Valley Virus 3Cpro Substrate Optimization Yields Efficient Substrates for use in Peptide-Prodrug Therapy.MYC, MAX, and small cell lung cancer.CRISPR Libraries and Screening.Target engagement imaging of PARP inhibitors in small-cell lung cancer.Fc-mediated Anomalous Biodistribution of Therapeutic Antibodies in Immunodeficient Mouse Models.Small-cell lung cancer in 2016: Shining light on novel targets and therapies.Combined Inhibition of NEDD8-Activating Enzyme and mTOR Suppresses NF2 Loss-Driven Tumorigenesis.Histone Code Aberrancies in Small Cell Lung Cancer.ProteomeGenerator: A framework for comprehensive proteomics based on de novo transcriptome assembly and high-accuracy peptide mass spectral matchingTalazoparib Is a Potent Radiosensitizer in Small Cell Lung Cancer Cell Lines and XenograftsONECUT2 is a driver of neuroendocrine prostate cancerTargeting NOTCH activation in small cell lung cancer through LSD1 inhibitionPeptide-based PET quantifies target engagement of PD-L1 therapeuticsNew Approaches to SCLC Therapy: From the Laboratory to the ClinicRegenerative lineages and immune-mediated pruning in lung cancer metastasisVirus-Receptor Interactions and Virus Neutralization: Insights for Oncolytic Virus DevelopmentHER2-Mediated Internalization of Cytotoxic Agents in ERBB2 Amplified or Mutant Lung CancersNK cell-mediated cytotoxicity contributes to tumor control by a cytostatic drug combinationVirus-Receptor Interactions: Structural Insights For Oncolytic Virus Development
P50
Q35170413-557D727E-1737-4A3B-A34E-AC4969DADBDBQ35224606-BF3AD09B-22A2-41FA-B367-1BCAE9616CBAQ35238397-97154640-F59E-4D42-BE82-E6380CF17309Q35662216-12102CC5-5B36-4DB6-B9A5-CEDC2FC23053Q35878431-5CB342CB-AD1C-426F-934D-01304B978D9DQ36036608-A7D6E384-C72C-4BF5-835D-6F2B8E5F5CD6Q36042596-04AD9FBA-7233-49DA-A7E0-C9120170CC3AQ36128151-8AB8C7CC-FDC2-4957-A094-1A995FFBCAC6Q37042256-4F6CC730-AA6A-49FD-B900-21F98B364D50Q37339265-3FF34649-CB2A-463E-8609-8313B14DE204Q37463325-12BF0DAB-1BA6-4649-BF8E-7D6B0C63B9A2Q38769421-D32DC5A0-C369-4F18-B499-36CCA9B96DEEQ38791259-14EF98CA-046E-4061-BAC9-9E21470CEFCCQ39776608-3F217279-52FB-4E7E-89D2-EB305C30BAB7Q39934413-30058285-4579-4D74-8DDE-C64B1D3E92D9Q40145604-57A50013-0E68-4557-8F25-2A002D98C4C2Q40208474-56EA28C2-383E-4E59-83FC-04816BBC7DF6Q40336402-3B70972B-4A77-4C23-8FBB-1B16C7E941EEQ40640808-0F537FA6-DEE1-49E2-B5A3-238D6AD22864Q41848124-9BB32FDE-E7B5-471C-BBBE-A1EE49DF47BAQ41992348-203FE16A-50EC-4CFB-AA0F-8814EECE3536Q42740602-095A28F4-9BD5-4799-B8D0-0A803DD93732Q43627373-C0A1AAF2-384D-4E22-9769-7B50961250D5Q47576454-7328600F-20BA-4402-BCDE-7B367E78F7FCQ48251246-BC510488-DF92-4EBF-8EC5-62915FB28B20Q49832498-5221EE17-C604-4EBF-9D35-0F059013AF91Q52813956-5A166043-EFAE-4377-9FAC-ABF0D8BA7AD6Q53316010-3C079B7F-D5EE-4CDE-858A-55E16B6B88E8Q53400102-9EF6FE2D-27C7-4D32-8E46-33FF3D6002E2Q57181405-F2923127-9B61-4757-B181-F67F6DC025E0Q57462253-02CA898D-8112-4975-A11A-927EA7CECA0CQ60907546-3F2D69B5-36E0-47C8-8FCB-E2AAB6C18328Q63866205-13D9273F-AE40-4908-9B67-AF372874F1C9Q64229921-5087298B-2013-4216-91E2-17F815C74CEDQ89527853-E4A77724-41E5-4DC0-BAD1-ECBC3C006B69Q89637977-FF110F30-F6FD-4CE3-9490-36BE1FFE388CQ90414077-AC68ED88-2A8C-493F-A457-0000C3066AF7Q90659981-6B367244-0268-4982-906C-CD0E986B1EBFQ90680882-C54F0A11-3006-4414-9EC2-202C673D0C3EQ91388498-CC3C80FD-5FD0-4E43-99E7-A883C4060670
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
John T Poirier
@ast
John T Poirier
@en
John T Poirier
@es
John T Poirier
@nl
type
label
John T Poirier
@ast
John T Poirier
@en
John T Poirier
@es
John T Poirier
@nl
prefLabel
John T Poirier
@ast
John T Poirier
@en
John T Poirier
@es
John T Poirier
@nl
P106
P31
P496
0000-0001-9795-5644